CA
NZ
UK
AU
IND
US
Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares closed up 23% at $2.56 following its second-quarter 2026 update, which emphasized enhanced capital reserves via a $12.0 million private placement.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares fell 17% to $0.33 after the company announced it will implement a 1-for-20 reverse share split, with post-split Nasdaq trading expected to begin September 14, 2026.
Headquartered in Brisbane, California, Pacira markets EXPAREL, a long-acting local anesthetic; ZILRETTA, an extended-release injection for knee osteoarthritis pain; and, until mid-2026, iovera, a handheld cryoanalgesia device. In late June 2026 the company agreed to divest the iovera business to Zimmer Biomet for up …
Aspira, headquartered in Shelton, Connecticut, specializes in ovarian-cancer risk assessment through its OvaSuite portfolio, which pairs the FDA-cleared Ova1 and Overa tests with the newer Ova1Plus reflex process and the OvaWatch monitoring test. In 2026 the company has pushed to broaden itsFranchisebeyond ovarian cancer. …
Incorporated in Luxembourg andManufacturingin Reykjavik, Iceland, Alvotech develops and producesBiosimilarsthat global partners commercialize, and it already has several approved products on the market. In late August 2026 the company said the U.S. Food and Drug Administration accepted for review its Biologics License Application for …
Alaunos now describes itself as a developer of oral therapeutics targeting obesity as a potential alternative to injectable GLP-1 drugs. Its lead candidate, ALN1003, has generated positive preclinical proof-of-concept data, with the company reporting metabolic improvements, including weight loss and improved insulin sensitivity, in …
SOHM develops, manufactures, markets and distributes generic and private-label pharmaceutical products in the United States, spanning analgesics, antibiotics, anti-cold and anti-inflammatory medicines, along with cosmeceutical and nutraceutical lines. More recently, the company has promoted a gene-editing effort branded ABBIE and a collaboration with Coastar …
Ultragenyx develops treatments for rare and ultra-rare genetic diseases, spanning approved products such as Crysvita, Dojolvi and Mepsevii alongside a deep gene-therapy and RNA pipeline. In August 2026, the company disclosed U.S. FDA approval of GENGLYCOS, its gene therapy for Glycogen Storage Disease Type …
Agios is built around PYRUKYND (mitapivat), an oral pyruvate kinase activator, following the company's earlier exit from oncology. Its most consequential near-term event is regulatory: the FDA granted priority review to a supplemental application for mitapivat in sickle cell disease, with a decision date …
Axim develops diagnostic healthcare solutions for ophthalmological conditions, including point-of-care tests for dry eye disease and allergic conjunctivitis, and it has operated a center for custom biomarker and biopharmaceutical research. The most consequential recent corporate event, however, is regulatory housekeeping rather than product news: …
Please wait processing your request...